This exploration compound was initially reported by Hoffman-La Roche in 2009. It’s amongst a number of benzodiazepines inside the imidazobenzodiazepine subgroup considered to offer nootropic Added benefits. The potency and protection of this compound will not be perfectly understood. Demoxepam isn't a preferred investigation chemical and has not been authorised https://joschkax814osv2.wikiannouncing.com/user